Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

René J Wiezer

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Journal of Clinical Pharmacology|October 12, 2014
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpointJeroen Diepstraten, Esther J H Janssen, Christian M Hackeng, et al.
Obesity Surgery|February 4, 2012
Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese PatientsJeroen Diepstraten, Christian M Hackeng, Simone van Kralingen, et al.
Clinical Pharmacokinetics|August 22, 2014
Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteersMargreke J E Brill, Anne van Rongen, Aletta P I Houwink, et al.
Clinical Pharmacokinetics|October 7, 2011
Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patientsSimone van Kralingen, Jeroen Diepstraten, Mariska Y M Peeters, et al.
Obesity Surgery|November 3, 2023
Preoperative Weight Gain Is Not Related to Lower Postoperative Weight Loss, But to Lower Total Weight Loss up to 3 Years After Bariatric-Metabolic SurgeryAnne Jacobs, May Al Nawas, Laura N Deden, et al.
Annals of Surgical Oncology|January 24, 2026
Absolute Bioavailability of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC): Systemic Pharmacokinetics of the CRC-PIPAC-II TrialTeun B M van den Heuvel, Paulien Rauwerdink, Emma Hulshof, et al.
British Journal of Cancer|February 23, 2022
Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacityJamila Laoukili, Alexander Constantinides, Emma C E Wassenaar, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 6, 2024
An observational cohort of patients with colorectal peritoneal metastases or pseudomyxoma peritonei treated with CRS-HIPEC: Development and first results of the Dutch CRS-HIPEC quality registryFelice N van Erning, Teun B M van den Heuvel, Femke P C Sijtsma, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 21, 2024
First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)Paulien Rauwerdink, Vincent C J van de Vlasakker, Emma C E Wassenaar, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Journal of Clinical Pharmacology|October 12, 2014
Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpointJeroen Diepstraten, Esther J H Janssen, Christian M Hackeng, et al.
Obesity Surgery|February 4, 2012
Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese PatientsJeroen Diepstraten, Christian M Hackeng, Simone van Kralingen, et al.
Clinical Pharmacokinetics|August 22, 2014
Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteersMargreke J E Brill, Anne van Rongen, Aletta P I Houwink, et al.
Clinical Pharmacokinetics|October 7, 2011
Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patientsSimone van Kralingen, Jeroen Diepstraten, Mariska Y M Peeters, et al.
Obesity Surgery|November 3, 2023
Preoperative Weight Gain Is Not Related to Lower Postoperative Weight Loss, But to Lower Total Weight Loss up to 3 Years After Bariatric-Metabolic SurgeryAnne Jacobs, May Al Nawas, Laura N Deden, et al.
Annals of Surgical Oncology|January 24, 2026
Absolute Bioavailability of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC): Systemic Pharmacokinetics of the CRC-PIPAC-II TrialTeun B M van den Heuvel, Paulien Rauwerdink, Emma Hulshof, et al.
British Journal of Cancer|February 23, 2022
Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacityJamila Laoukili, Alexander Constantinides, Emma C E Wassenaar, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 6, 2024
An observational cohort of patients with colorectal peritoneal metastases or pseudomyxoma peritonei treated with CRS-HIPEC: Development and first results of the Dutch CRS-HIPEC quality registryFelice N van Erning, Teun B M van den Heuvel, Femke P C Sijtsma, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 21, 2024
First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II)Paulien Rauwerdink, Vincent C J van de Vlasakker, Emma C E Wassenaar, et al.
Pageof 1